caa a22 4500 445356847 CHVBK 20180317142903.0 cr unu---uuuuu 170323e20111101xx s 000 0 eng 10.1007/s10072-011-0800-4 doi (NATIONALLICENCE)springer-10.1007/s10072-011-0800-4 Lecture: fotemustine in brain tumors [Elektronische Daten] [A. Silvani, P. Gaviani, E. Lamperti, A. Botturi, D. Ferrari, G. Simonetti, A. Salmaggi] Fotemustine (FTMS) is a third-generation nitrosourea, in preclinical studies, FTMS compared favorably with carmustine (BCNU) and lomustine (CCNU) against several human tumor cell lines. In conventional schedule, FTMS is administered at a dose of 100mg/sqm/week for three consecutive weeks as induction (I) treatment, followed by 100mg/sqm every three weeks, after a 5-week rest, as maintenance (M). Several Italian groups reported the results using FTMS in malignant glioma patients recurring after temozolomide standard treatment. In these papers, the 6-progression free survival are ranging from 20 to 52%. With the schedule (I+M) myelosuppression is observed in more than 30% of patients, and thrombocytopenia and leukopenia are more frequent and significant in Temozolomide pretreated patients. On the bases of the hematological toxicities several authors experimented new schedules of FTMS administrated at low doses. Recently, some authors reported the interesting results of a multicenter study on recurrent glioblastoma multiforme patients combining FTMS with new antiangiogentic agent bevacizumab. Springer-Verlag, 2011 Fotemustine nationallicence Nitrosourea nationallicence Alkilating agents nationallicence Glioblastoma recurrent nationallicence Silvani A. Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 11 Via Celoria, 20133, Milan, Italy aut Gaviani P. Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 11 Via Celoria, 20133, Milan, Italy aut Lamperti E. Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 11 Via Celoria, 20133, Milan, Italy aut Botturi A. Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 11 Via Celoria, 20133, Milan, Italy aut Ferrari D. Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 11 Via Celoria, 20133, Milan, Italy aut Simonetti G. Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 11 Via Celoria, 20133, Milan, Italy aut Salmaggi A. Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 11 Via Celoria, 20133, Milan, Italy aut Neurological Sciences Springer Milan 32(2011-11-01), 255-257 1590-1874 32<255 2011 32 10072 https://doi.org/10.1007/s10072-011-0800-4 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10072-011-0800-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Silvani A. Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 11 Via Celoria, 20133, Milan, Italy aut NATIONALLICENCE 700 1- Gaviani P. Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 11 Via Celoria, 20133, Milan, Italy aut NATIONALLICENCE 700 1- Lamperti E. Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 11 Via Celoria, 20133, Milan, Italy aut NATIONALLICENCE 700 1- Botturi A. Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 11 Via Celoria, 20133, Milan, Italy aut NATIONALLICENCE 700 1- Ferrari D. Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 11 Via Celoria, 20133, Milan, Italy aut NATIONALLICENCE 700 1- Simonetti G. Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 11 Via Celoria, 20133, Milan, Italy aut NATIONALLICENCE 700 1- Salmaggi A. Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 11 Via Celoria, 20133, Milan, Italy aut NATIONALLICENCE 773 0- Neurological Sciences Springer Milan 32(2011-11-01), 255-257 1590-1874 32<255 2011 32 10072 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer